Quantum Biopharma Ltd.
QNTM Healthcare Biotechnology
In the quarter to June 2026, EPS grew 85.5% and free cash flow grew 5.88%, each against the same quarter a year earlier.
Follow QNTM
Quantum Biopharma Ltd. (QNTM) Altman Z-score
Quantum Biopharma Ltd.'s Altman Z-score for fiscal 2018 is 22790.92, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2019 | −0.26 | (22,791.19) |
| FY2018 | 22790.92 | — |
How fiscal 2018’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.39 | — | 0.47 | |
| Retained earnings / total assets | (0.50) | — | −0.70 | |
| EBIT / total assets | (0.62) | — | −2.05 | |
| Market value of equity / total liabilities | 37,988.67 | — | 22793.20 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Safe zone | 22790.92 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 27.51 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| QNTM Quantum Biopharma Ltd. | −0.3× |
| EVAX Evaxion A/S - Sponsored ADR compare | −4.5× |
| IMMP Prima BioMed Ltd compare | −10.5× |
| BYSI BeyondSpring Inc. compare | −12.5× |
| KYNB Kyntra Bio Inc compare | −20.3× |
| ESLA Estrella Immunopharma, Inc. compare | — |
| PLRZ Polyrizon Ltd. compare | — |
| CNTX Context Therapeutics Inc. compare | — |
| CYAD Celyad SA compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets